AUTHOR INDEX

Abiaka, C., Al-Awaki, F., Gulshan, S., Al-Sayer, H., Behbehani, A., Farghaly, M. & Simbeye, A. Plasma concentrations of alpha-tocopherol and urate in patients with different types of cancer, 265
Aden Abdi, Y. *see* Nsimba, S.E.D.
Ahmadi-Abhari, S.A., Akhondzadeh, S., Assadi, S.M., Shabestari, O.L., Farzanehgan, Z.M. & Kamlipour, A. Baclofen versus clonidine in the treatment of opiates withdrawal, side effects aspect: a double-blind randomized control trial, 67
Akarca, U.S. *see* Ersoz, G.
Akhondzadeh, S. *see* Ahmadi-Abhari, S.A.
Akhondzadeh, S., Kashani, L., Mobaseri, M., Hosseini, S.H., Nikzad, S. & Khani, M. Passionflower in the treatment of opiates withdrawal: a double-blind randomized controlled trial, 369
Akhondzadeh, S., Naghavi, H.R., Vazirian, M., Shayeganpour, A., Rashidi, H. & Khani, M. Passionflower in the treatment of generalized anxiety: a pilot double-blind randomized controlled trial with oxazepam, 363
Alam, S.M. *see* Tutunji, M.
Al-Awaki, F. *see* Abiaka, C.
Alberti, C. *see* Venturini, F.
Alberti, M.P. *see* Venturini, F.
Alm, C. *see* Nsimba, S.E.D.
Al-Sayer, H. *see* Abiaka, C.
Amagai, T. *see* Nakamura, H.
Ammar, R. *see* Caron, M.F.
Assadi, S.M. *see* Ahmadi-Abhari, S.A.
Avery, A.J. *see* Chen, Y.-F.

Ballantyne, S. *see* Sarkar, P.K.
Barthélémy, C. *see* Odou, P.
Behbehani, A. *see* Abiaka, C.
Belmonte-De-Abreu, P. *see* Brunstein, M.G.
Berdowska, A. & Zwirska-Korczala, K. Neopterin measurement in clinical diagnosis, 319
Bernard, L., El-Hajj, L., Pron, A., Lotthé, V., Gleizes, F., Signoret, Ph., Denormandie, J.L., Gaillard, C. & Perronne, C. Outpatient parenteral antimicrobial therapy (OPAT) for the treatment of osteomyelitis: evaluation of efficacy, tolerance and cost, 445
Bheekie, A., Syce, J.A. & Weinberg, E.G. Peak expiratory flow rate and symptom self-monitoring of asthma initiated from community pharmacies, 287
Bigeleisen, P.E. & Wempe, M. Identification of the precipitate in alkalinized solutions of mepivacaine and bupivacaine at 37 °C, 171
Bondareva, I.B., Sokolov, A.V., Tischenkova, I.F. & Jelliffe, R.W. Population pharmacokinetic modelling of carbamazepine by using the iterative Bayesian (IT2B) and the nonparametric EM (NPEM) algorithms: implications for dosage, 213
Brunstein, M.G., Belmonte-De-Abreu, P., Souza, D.O. & Lara, D.R. Therapeutic benefit of adjunctive dipyridamole in schizophrenia is probably due to adenosine–glutamate interactions, 155
Byrom, B. *see* Green, H.

Calvo, M. *see* Pina Latorre, M.A.
Campbell, S.M. & Cantrill, J.A. Consensus methods in prescribing research, 5
Cantrill, J.A. *see* Campbell, S.M.
Carcas, A. *see* Guerra, P.
Caron, M.F. *see* Folstad, J.
Caron, M.F., Song, J., Ammar, R., Kluger, J. & White, C.M. An evaluation of the change in electrocardiograph P-wave variables after acute caffeine ingestion in normal volunteers, 145
Catalán, C. *see* Pina Latorre, M.A.
Chapman, S.R. Prescribing information systems; making sense of primary care data, 235
Chehne, F. *see* Sinzinger, H.
Chen, L.C., Chou, M.H., Lin, M.F. & Yang, L.L. Effects of Paeonidae Radix, a traditional Chinese medicine, on the pharmacokinetics of phenytoin, 271
Chen, Y.-F., Dewey, M.E. & Avery, A.J. Self-reported medication use for older people in England and Wales, 129
Chou, M.H. *see* Chen, L.C.
Connor, J.P. *see* Feeney, G.F.X.
Conway, S.P. *see* Walters, M.P.
Cooke, C. *see* Pearson, G.J.
Czajkowski, F. *see* Feeney, G.F.X.

D'Souza, C. *see* Sarkar, P.K.
De Beule, K. *see* Willems, L.
Denekens, J. *see* Vermeire, E.
Denormandie, J.L. *see* Bernard, L.
Dewey, M.E. *see* Chen, Y.-F.
Dham, R. *see* Tutunji, M.
Do Prado-Lima, P., Knijnik, L., Juruena, M. & Padilla, A. Lithium reduces maternal child abuse behaviour: a preliminary report, 279
Dörr, H.G. *see* Schroth, M.
Dötsch, J. *see* Schroth, M.

El-Hajj, L. *see* Bernard, L.
Ericsson, O. *see* Nsimba, S.E.D.
Ersoz, G., Karasu, Z., Yildiz, C., Akarca, U.S. & Yuce, G. Severe toxic hepatitis associated with amoxycillin and clavulanic acid, 225
Evans, J.M.M. *see* Libby, G.

Farghaly, M. *see* Abiaka, C.
Farzanehgan, Z.M. *see* Ahmadi-Abhari, S.A.
Feeney, G.F.X., Connor, J.P., Young, R.McD., Tucker, J. & Czajkowski, F. Adherence with naltrexone

© 2001 Blackwell Science Ltd

prescription advice in hospital outpatient alcohol rehabilitation programme, 73
Fernández, A. *see* Guerra, P.
Folstad, J., Caron, M.F., Nguyen, I. & White, C.M. Assessment of weight-based versus standard-dosing of heparin in patients with unstable angina, 283
Frías, J. *see* Guerra, P.
Furberg, C.D. *see* Sinzinger, H.

Gaillard, C. *see* Bernard, L.
Gardner, D. *see* McGrath, A.M.
George, J., Nuttall, S.L. & Kendall, M.J. Prostate cancer and antioxidants, 231
Ghani, S. *see* Green, H.
Gill, P.S. & Roalfe, A. Antibiotic prescribing by single-handed general practitioners: secondary analysis of data, 195
Gill, P.S. & Roalfe, A. Determinants of prescribing costs amongst single-handed general practitioners, 433
Gleizes, F. *see* Bernard, L.
Gönenç, A., Özkan, Y., Torun, M. & Simsek, B. Plasma malondialdehyde (MDA) levels in breast and lung cancer patients, 141
Goto, Y. *see* Yukawa, E.
Govantes, C. *see* Guerra, P.
Green, H., McEntegart, D.J., Byrom, B., Ghani, S. & Shepherd, S. Minimisation in crossover trials with non-prognostic strata: theory and practical application, 121
Guerra, P., Frías, J., Ruiz, B., Soto, A., Carcas, A., Govantes, C., Montuenga, C. & Fernández, A. Bioequivalence of allopurinol and its metabolite oxipurinol in two tablet formulations, 113
Gulshan, S. *see* Abiaka, C.
Gustafsson, L.L. *see* Nsimba, S.E.D.

Hashiguchi, A. *see* Inoue, N.
Hearnshaw, H. *see* Vermeire, E.
Helin-Tanninen, M., Naaranlahti, T., Kontra, K. & Ojanen, T. Enteral suspension of nifedipine for neonates. Part 2: stability of an extemporaneously compounded nifedipine suspension, 59
Helin-Tanninen, M., Naaranlahti, T., Kontra, K. & Wallenius, K. Enteral suspension of nifedipine for neonates. Part 1. Formulation of nifedipine suspension for hospital use, 49
Higuchi, S. *see* Yukawa, E.
Hirakawa, M. *see* Sendo, T.
Hirakawa, Y. *see* Makino, K.
Hori, T. *see* Nakamura, H.
Hosseini, S.H. *see* Akhondzadeh, S.
Hussein, A. *see* Teh, L.K.

Ikebukuro, K. *see* Nakamura, H.
Ikeda, A. *see* Makino, K.
Inoue, N., Kihara, K., Hashiguchi, A., Maehara, F., Yoshioka, S. & Ushio, Y. Cerebral embolism and hormone replacement therapy, 181
Isa, M.N. *see* Teh, L.K.
Ismail, R. *see* Teh, L.K.
Itokazu, N. *see* Kodama, H.
Iwakawa, M. *see* Nakamura, H.

Jarrar, O. *see* Tutunji, M.
Jassim Al Khaja, K.A., Sequeira, R.P. & Mathur, V.S. Rational pharmacotherapy of hypertension in the elderly: analysis of the choice and dosage of drugs, 33
Jelliffe, R.W. *see* Bondareva, I.B.
Jesson, J. Cross-sectional studies in prescribing research, 397
Juruena, M. *see* Do Prado-Lima, P.

Kajdaniuk, D., Marek, B. & Kos-Kudla, B. Influence of adjuvant chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil on plasma melatonin and chosen hormones in breast cancer pre-menopausal patients, 297
Kamlipour, A. *see* Ahmadi-Abhari, S.A.
Kaneko, M. *see* Nakamura, H.
Kanemaru, R. *see* Kodama, H.
Karasu, Z. *see* Ersoz, G.
Kashani, L. *see* Akhondzadeh, S.
Kataoka, Y. *see* Makino, K.
Kataoka, Y. *see* Sendo, T.
Kataoka, Y. *see* Teshima, D.
Kendall, M.J. *see* George, J.
Kendall, M.J. *see* Langford, N.J.
Kendall, M.J. *see* Nuttall, S.L.
Khani, M. *see* Akhondzadeh, S.
Khani, M. *see* Akhondzadeh, S.
Kihara, K. *see* Inoue, N.
Kilwein, J.H. The noncompliance blame game, 157
Kluger, J. *see* Caron, M.F.
Knijnik, L. *see* Do Prado-Lima, P.
Kodama, H., Kodama, Y., Itokazu, N., Shinozawa, S., Kanemaru, R. & Sugimoto, T. Effect of temperature on serum protein binding characteristics of phenytoin in monotherapy paediatric patients with epilepsy, 175
Kodama, Y. *see* Kodama, H.
Kontra, K. *see* Helin-Tanninen, M.
Kontra, K. *see* Helin-Tanninen, M.
Kos-Kudla, B. *see* Kajdaniuk, D.
Kuroda, T. *see* Yukawa, E.

Langford, N.J. & Kendall, M.J. Rhabdomyolysis with HMG CoA reductase inhibitors: a class effect?, 391
Langford, N.J. *see* Nuttall, S.L.
Lara, D.R. *see* Brunstein, M.G.
Libby, G., Macdonald, T.M. & Evans, J.M.M. Record-linkage methodology for prescribing research, 241
Lin, M.F. *see* Chen, L.C.
Lloyd, D.C.E.F. & Scrivener, G. Prescribing at the Primary Care Group level: census data and prescribing, 93
Lotthé, V. *see* Bernard, L.
Lupattelli, G. *see* Marchesi, S.
Lupattelli, G. *see* Sinzinger, H.
Luscombe, D.K. *see* Tremlett, H.L.

MacDonald, T.M. *see* Libby, G.
Maehara, F. *see* Inoue, N.
Makino, K. *see* Sendo, T.
Makino, K. *see* Teshima, D.

Makino, K., Kataoka, Y., Hirakawa, Y., Ikeda, A., Yamauchi, A. & Oishi, R. A leucine(7)-to-proline(7) polymorphism in the signal peptide of neuropeptide Y was not identified in the Japanese population, 201
Mannarino, E. *see* Marchesi, S.
Marchesi, S., Lupattelli, G., Siepi, D., Roscini, A.R., Vaudo, G., Sinzinger, H. & Mannarino, E. Oral - arginine administration attenuates postprandial endothelial dysfunction in young healthy males, 343
Marek, B. *see* Kajdaniuk, D.
Massele, A.Y. *see* Nsimba, S.E.D.
Mathur, V.S. *see* Jassim Al Khaja, K.A.
McCormack, J. *see* McGrath, A.M.
McEntegart, D.J. *see* Green, H.
McGrath, A.M., Gardner, D. & McCormack, J. Is home peak expiratory flow monitoring effective for controlling asthma symptoms?, 311
Mobaseri, M. *see* Akhondzadeh, S.
Modrego, P.J. *see* Pina Latorre, M.A.
Montuenga, C. *see* Guerra, P.
Musameh, M. *see* Tutunji, M.

Naaranlahti, T. *see* Helin-Tanninen, M.
Naaranlahti, T. *see* Helin-Tanninen, M.
Nagahama, H. *see* Teshima, D.
Naghavi, H.R. *see* Akhondzadeh, S.
Nakamura, H., Tanaka, E., Kaneko, M., Iwakawa, M., Hori, T., Ikebukuro, K., Amagai, T. & Ohkawa, H. The clinical importance of the trimethadione tolerance test as a method for quantitative assessment of hepatic functional reserve in patients with biliary atresia, 417
Nakashima, K. *see* Sendo, T.
Nguyen, I. *see* Folstad, J.
Nikzad, S. *see* Akhondzadeh, S.
Nonaka, T. *see* Yukawa, E.
Nsimba, S.E.D., Aden Abdi, Y., Rimoy, G., Massele, A.Y., Alm, C., Ericsson, O. & Gustafsson, L.L. A comparative *in vitro* and *in vivo* study of a sugar-coated chloroquine preparation marketed in Tanzania versus an ordinary brand, 43
Nuttall, S.L, Langford, N.J. & Kendall, M.J. Beta-blockers in heart failure. 2. Mode of action, 1
Nuttall, S.L. *see* George, J.

Odou, P., Barthélémy, C. & Robert, H. Influence of seven beverages on salicylate disposition in humans, 187
Oguogho, A. *see* Sinzinger, H.
Ohdo, S. *see* Yukawa, E.
Ohkawa, H. *see* Nakamura, H.
Oishi, R. *see* Makino, K.
Oishi, R. *see* Sendo, T.
Oishi, R. *see* Teshima, D.
Ojanen, T. *see* Helin-Tanninen, M.
Özkan, Y. *see* Gönenç, A.

Padilla, A. *see* Do Prado-Lima, P.
Pearson, G.J., Cooke, C., Simmons, W.K.T. & Sketris, I. Evaluation of the use of evidence-based angiotensin-converting enzyme inhibitor criteria for the treatment of congestive heart failure: opportunities for pharmacists to improve patient outcomes, 351
Perronne, C. *see* Bernard, L.
Pina Latorre, M.A., Modrego, P.J., Rodilla, F., Catalán, C. & Calvo, M. Parkinsonism and Parkinson's disease associated with long-term administration of sertraline, 111
Pron, A. *see* Bernard, L.

Quamruzaman, R. *see* Tutunji, M.

Raffa, R.B. Antihistamines as analgesics, 81
Raffa, R.B. Pharmacology of oral combination analgesics: rational therapy for pain, 257
Rahman, A.R.A. *see* Teh, L.K.
Rashidi, H. *see* Akhondzadeh, S.
Rimoy, G. *see* Nsimba, S.E.D.
Roalfe, A. *see* Gill, P.S.
Roalfe, A. *see* Gill, P.S.
Robert, H. *see* Odou, P.
Rodilla, F. *see* Pina Latorre, M.A.
Roscini, A.R. *see* Marchesi, S.
Ruiz, B. *see* Guerra, P.

Sarkar, P.K., D'Souza, C. & Ballantyne, S. Treatment of aneurysmal subarachnoid haemorrhage in elderly patients, 247
Satou, M. *see* Yukawa, E.
Schroth, M., Dötsch, J. & Dörr, H.G. Hypercalcemia and idiopathic hypoparathyroidism, 453
Scrivener, G. *see* Lloyd, D.C.E.F.
Scroccaro, G. *see* Venturini, F.
Sendo, T., Hirakawa, M., Makino, K., Nakashima, K., Kataoka, Y. & Oishi, R. Particulate contamination of localized amphotericin B preparation during reconstitution process, 87
Sequeira, R.P. *see* Jassim Al Khaja, K.A.
Shabestari, O.L. *see* Ahmadi-Abhari, S.A.
Shayeganpour, A. *see* Akhondzadeh, S.
Shepherd, S. *see* Green, H.
Shinozawa, S. *see* Kodama, H.
Siepi, D. *see* Marchesi, S.
Signoret, Ph. *see* Bernard, L.
Simbeye, A. *see* Abiaka, C.
Simmons, W.K.T. *see* Pearson, G.J.
Simsek, B. *see* Gönenç, A.
Sinzinger, H. *see* Marchesi, S.
Sinzinger, H., Lupattelli, G., Chehne, F., Oguogho, A. & Furberg, C.D. Isoprostane 8-epi-PDF_2 is frequently increased in patients with muscle pain and/or CK-elevation after HMG-Co-enzyme-A-reductase inhibitor therapy, 303
Sketris, I. *see* Pearson, G.J.
Sokolov, A.V. *see* Bondareva, I.B.
Song, J. *see* Caron, M.F.
Soto, A. *see* Guerra, P.
Souza, D.O. *see* Brunstein, M.G.
Sugimoto, T. *see* Kodama, H.
Syce, J.A. *see* Bheekie, A.

Tanaka, E. *see* Nakamura, H.
Taniyama, T. *see* Teshima, D.

Teh, L.K., Ismail, R., Yusoff, R., Hussein, A., Isa, M.N. & Rahman, A.R.A. Heterogeneity of *CYP2D6* gene among Malays in Malaysia, 205
Teshima, D., Nagahama, H., Makino, K., Kataoka, Y. & Oishi, R. Microanalysis of propofol in human serum by semi-microcolumn high-performance liquid chromatography with UV detection and solid-phase extraction, 381
Teshima, D., Taniyama, T. & Oishi, R. Usefulness of forced diuresis for acute boric acid poisoning in an adult, 387
Tischenkova, I.F. *see* Bondareva, I.B.
Topcu, Z. DNA topoisomerases as targets for anti-cancer drugs, 405
Torun, M. *see* Gönenç, A.
Tremlett, H.L., Luscombe, D.K. & Wiles, C.M. Prescribing for multiple sclerosis patients in general practice: a case-control study, 437
Tucker, J. *see* Feeney, G.F.X.
Tutunji, M., Jarrar, O., Musameh, M., Alam, S.M., Quamruzaman, R. & Dham, R. Bioequivalence evaluation of two brands of cefaclor 500 mg capsules: quantification of cefaclor using solid phase extraction technique, 149

Ushio, Y. *see* Inoue, N.

Van Der Geest, R. *see* Willems, L.
Van Royen, P. *see* Vermeire, E.
Vaudo, G. *see* Marchesi, S.
Vazirian, M. *see* Akhondzadeh, S.
Venturini, F., Alberti, C., Alberti, M.P. & Scroccaro, G. Clinical trials in Italy: focus on the protocols submitted to Ethics Committees, 103
Venugopal, J. Cardiac natriuretic peptides – hope or hype?, 15
Vermeire, E., Hearnshaw, H., Van Royen, P. & Denekens, J. Patient adherence to treatment: three decades of research. A comprehensive review, 331

Wallenius, K. *see* Helin-Tanninen, M.
Walters, M.P. & Conway, S.P. Cholesterol esterase activities in commercial pancreatic preparations and implications for use in pancreatic exocrine insufficient cystic fibrosis, 425
Weinberg, E.G. *see* Bheekie, A.
Wempe, M. *see* Bigeleisen, P.E.
White, C.M. *see* Caron, M.F.
White, C.M. *see* Folstad, J.
Wiles, C.M. *see* Tremlett, H.L.
Willems, L., Van Der Geest, R. & De Beule, K. Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics, 159

Yamauchi, A. *see* Makino, K.
Yang, L.L. *see* Chen, L.C.
Yildiz, C. *see* Ersoz, G.
Yoshioka, S. *see* Inoue, N.
Young, R.McD. *see* Feeney, G.F.X.
Yuce, G. *see* Ersoz, G.
Yukawa, E., Satou, M., Nonaka, T., Yukawa, M., Ohdo, S., Higuchi, S., Kuroda, T. & Goto, Y. Influence of age and comedication on steady-state clonazepam serum level–dose ratios in Japanese epileptic patients, 375
Yukawa, M. *see* Yukawa, E.
Yusoff, R. *see* Teh, L.K.

Zwirska-Korczala, K. *see* Berdowska, A.

Journal of Clinical Pharmacy and Therapeutics (2001) **26**, 461–462

KEYWORD INDEX

8-epi-$PDF_{2\alpha}$, 303

Action plan, 311
Adherence, 331
Adverse effects, 111
Aggression, 279
Alcohol dependence, 73
Alkalinization, 171
Allele frequency, 205
Alpha-tocopherol, 265
Amoxycillin, 225
Amphotericin B, 87
Analgesia, 257
Analgesics, 81
Angiotensin-converting enzyme inhibitors, 351
ANP, 15
Antibiotic prescribing, 195
Anticarcinogenic drug, 405
Anti-craving, 73
Antiepileptic drug, 375
Antihistamine, 81
Antihypertensive drugs, 33
Antimicrobial therapy, 445
Aspirin, 187
Asthma, 287, 311
Atrial fibrillation, 145

Baclofen, 67
Beverages, 187
Biliary atresia, 417
Bioequivalence, 149
BNP, 15
Boric acid, 387
Breast cancer, 141, 181, 297

Caffeine, 145
Cancer, 265
Carbamazepine pharmacokinetics, 213
Carbamazepine, 375
Carboxyl ester lipase, 425
Cefaclor, 149
Cell mediated immunity, 311
Cerebral embolism, 181
Chemotherapy, 297
Child abuse, 279
Chloroquine, 43
Cholesterol esterase, 425
Clavulanic acid, 225
Clinical trials, 103
Clonazepam, 375
Clonidine, 369
Combination therapy, 257
Community pharmacy, 287
Congestive heart failure, 351
Consensus methods, 5
Controlled trial, 297
Cost, 445
Creatinine phosphokinase (CK), 303
Crossover trials, 121
Cyclophosphamide, 297
CYP2D6 polymorphism, 205
Cystic fibrosis, 425

Databases, 241
De-ethylchloroquine, 43
Deprivation, 93
Detoxification, 369
Diet, 343
Diuresis, 387
Drug interaction, 375
Drug utilization, 129
Drug utilization evaluation (DUE), 351
Drug utilization review (DUR), 351

Efficacy, 257, 445
Elderly hypertensives, 33
Elderly patients, 247
Elderly, 129
Enzymes, 425
Epilepsy, 175
Esterification, 425
Ethics committees, 103
Ethnic difference, 205

Flow-mediated vasodilation, 343
Fluorouracil, 297
Functional hepatic reserve, 417
Fungal infection, 159
Furosemide, 387

General practice, 195, 433
General practitioner, 437
Guidelines, 351

Health beliefs, 331
Healthy volunteers, 43
Heparin, 283
Herbal medicines, 363
High performance liquid chromatography, 425
Histamine, 81
HMG-co-enzyme-A-reductase inhibitor, 303
Hormone replacement therapy, 181
Hormones, 297
HPLC, 149
Hypercalciuria, 453
Hypercalcemia, 453
Hyperlipoproteinemia, 303

ICU, 381
Idiopathic hypoparathyroidism, 453
Immobilization, 453
In vitro, 43
In vivo, 43
Interactions, 187
Interferon-γ, 311
Isoprostanes, 303
Itraconazole, 159

Japanese, 201

L-arginine, 343
Lipase, 425
Lipid peroxidation, 141
Lithium, 279
Liver disease, 417
Local anaesthetic, 171
Lung cancer, 141

Macrophages, 311
Malaria, 43
Malaysian Malays, 205
Malondialdehyde (MDA), 141
Melatonin, 297
Methadone, 369
Methotrexate, 297
Minimization, 121
Monocytes, 311
Monotherapy, 175
Morbidity, 93
Mortality, 93
Multi-drug resistance, 405
Multiple sclerosis, 437
Muscle pains, 303

Naltrexone, 73
Natriuretic, 15
Neonate, 49
Neopterin, 311
NEP, 15
Neuropeptide Y, 201
Neuropeptides, 81
Nifedipine, 49, 59
Novel formulation, 159

Opiate withdrawal, 67, 369
Outpatient parenteral osteomyelitis, 445
Oxidation injury, 303

Paediatrics, 175
Paeniae Radix, 271
Pain, 81, 257
Parkinson's disease, 111
Parkinsonism, 111
Particulate contamination, 87
Passiflora incarnata, 363
Passionflower, 369
Patient compliance, 331
PCGs, 93

© 2001 Blackwell Science Ltd

Peak expiratory flow, 311
PEFR, 287
Pharmacist, 103, 283, 397
Pharmacodynamics, 159
Pharmacokinetics, 43, 149, 159, 187, 271
Phenytoin, 175, 271
Physician–patient relationship, 331
Poisoning, 387
Polymorphism, 201
Population modelling, 213
Postmenopausal women, 181
Postprandial phase, 343
Precipitate, 171
Prescribing, 241, 437
Prescribing advice, 397
Prescribing cost variation, 433
Prescribing indicators, 93
Prescribing information systems, 235
Prescribing patterns, 33, 129
Prescribing research, 5
Propofol, 381
P-wave, 145

Quality indicators, 235

Randomized controlled trial, 369
RCT, 363, 369
Record-linkage, 241
Reduced glutathione, 343
Renal failure, 453

Salicylic acid, 187
Sedation, 381
Self-management, 287
Semi-microcolumn, 381
Sertraline, 111
Side effects, 67
Signal peptide of neuropeptide Y, 201
Silicone, 87
Stability, 59
Subarachnoid haemorrhage, 247
Substandard drugs, 43
Survey, 397
Suspension, 49, 59
Symptoms, 287
Synergy, 257

Therapeutic drug monitoring, 213
Tolerability, 257
Toxic hepatitis, 225
Traditional medicine, 363
Treatment, 247
Trimethadione tolerance test, 417
Type I DNA topoisomerase, 405
Type II DNA topoisomerase, 405

Unstable angina, 283
Urate, 265
Urine, 43

Valproic acid, 375
Variables, 145

Wagner–Nelson modified method, 187
Weight-based, 283
Whole blood, 43

X-ray analysis, 87